| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2004 | US20040039062 Urea particles coated with a non-rumen-degradable resin membrane that has thickness of 3-15 microns and a permeability which allows 20-70% of the urea to be dissolved in water in 10 hours at 39 degrees c |
| 02/26/2004 | US20040039061 Suppress expression and induction of inflammatory cytokines, cell adhesion molecule gene and virus and suppressors for nuclear factor kappa beta (nf-kb) |
| 02/26/2004 | US20040039060 Capable of chelating both of the two divalent metal ions at the same time, a prodrug or a solvate |
| 02/26/2004 | US20040039059 Use of n,n' -dibenzyl ethylene diamine-n, n'- diacetic acid derivatives as anti-pollution agent |
| 02/26/2004 | US20040039058 Identifying a mammal having elevated concentrations of tumor necrosis factor- alpha and administering stearidonic acid (18:4, n-3) over a time period |
| 02/26/2004 | US20040039057 Putrescine, spermine, spermidine or cadaverine with urea or lidocaine |
| 02/26/2004 | US20040039056 9-cis retinoic acid, pharmaceutically acceptable salts and hydrolyzable esters, prodrugs and metabolites thereof |
| 02/26/2004 | US20040039055 Ameliorate the negative side effects of a serum concentration of a drug higher than that used in normal clinical practice |
| 02/26/2004 | US20040039054 Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 02/26/2004 | US20040039053 Administering to a patient a (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives or salt, free of its (+) stereoisomer to treat the type II diabetes, gout, insulin resistance and atherosclerosis |
| 02/26/2004 | US20040039052 Urinary incontinence therapy |
| 02/26/2004 | US20040039051 Administering to a cancer patient a therapeutically effective amount of a dynamic platinum compound with reduced toxicity, and can be activated and deactivated reversibly depending on the biological environment |
| 02/26/2004 | US20040039050 Formulating phenanthro(1,2-b)-furan compound for eliminating hyperammonemia in the brain tissue for treating early stage Alzheimer's disease |
| 02/26/2004 | US20040039049 Stable amorphous calcium pseudomonate and processes for the preparation thereof |
| 02/26/2004 | US20040039048 Administration of (natural of synthetic) cannabinoids to (human or non-human) mammals having cerebral tumors, and cannabinoids are chosen from Delta 9- tetrahydrocannabinol, Delta 8-tetrahydrocannabinol, cannabinol and cannabidiol |
| 02/26/2004 | US20040039047 Administration by inhalation of therapeutically effective amounts of a compound containing a central sequiterpene epoxide structure or trichothecene to prevent the proliferation of neoplasms in the lungs of humans or animals |
| 02/26/2004 | US20040039046 Scyphostatin analogues as SMase inhibitors |
| 02/26/2004 | US20040039045 (2-azabicyclo(2.2.1)hept-7yl)methylcarbamate derivatives are useful for treating schizophrenia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Tourette's syndrome, age related memory loss and withdrawal symptoms |
| 02/26/2004 | US20040039044 Coupling under reducing conditions aminoalkylpyrrolidine-n-alkyl with one equivalant of a aldehyde compound; useful for treating pain, schizophrenia, depression and sleep disorders |
| 02/26/2004 | US20040039043 Amidobiphenyloxime derivatives, useful as fungicide or bactericide for protection of crops and materials |
| 02/26/2004 | US20040039042 Method of transdermal drug delivery |
| 02/26/2004 | US20040039041 Using an alfa2-adrenoceptor antagonist or an ester or salt selected from atipamezole, idazoxan, efaroxan or their salts, to prevent dyskinesias caused by chronic use of dopaminergic agents while treting neuropsychiatric disorders |
| 02/26/2004 | US20040039038 Biaromatic compound activators of PPARy-type receptors |
| 02/26/2004 | US20040039036 Oral solution containing famotidine and edetic acid or a salt |
| 02/26/2004 | US20040039035 A (Ar1-X-Ar2) compound, where Ar1 and Ar2= aryl, heteroaryl or fused arylheteroaryl, X= secondary or tertiary amine, -C(=O)S, -CH=CHSO2 and -SO2N(R)2, and R=H or alkyl, useful for treating contact hypersensitivity |
| 02/26/2004 | US20040039031 A combination of an antidiabetic biguanide and an antidiabetic sulfonamide, at low doses, in combination or as a mixture with inert excipient(s) |
| 02/26/2004 | US20040039030 Hydrocarbyl substituted 1-hydroxy-2-pyridones exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains |
| 02/26/2004 | US20040039029 Thiazolyl urea compounds and methods of uses |
| 02/26/2004 | US20040039026 Macromolecules such as (12R,13S,15S)-cyclopropyl 5-methyl-pyridine epothilone A, used as tubulin polymerization promoters and for cytolysis cancer cells; antiproliferative agents |
| 02/26/2004 | US20040039025 Substituted hydrazine derivatives |
| 02/26/2004 | US20040039024 Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them |
| 02/26/2004 | US20040039022 Storage stable mixtures of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, water, buffers and chelate compounds used as neuroprotectants |
| 02/26/2004 | US20040039021 Pharmaceutical anti-inflammatory aerosol formulation |
| 02/26/2004 | US20040039020 Novel pharmaceutical formulation suitable for nebulisation |
| 02/26/2004 | US20040039019 Hetreocyclic carboxy amines such as N-(2-Oxo-2,3-dihydro-1H-indol-6-yl)-2-((6-oxo-1,6-dihydro-pyridin-3 -ylmethyl)-amino)-benzamide, used for prophylaxis of arthritis, vision defects, diabetes, arteriosclerosis, skin or urogenital disorders |
| 02/26/2004 | US20040039018 CETP inhibitors in combination with antihypertensive agents and uses thereof |
| 02/26/2004 | US20040039017 Heterocyclic amines such as 2-(3-(4-Chloro-3-trifluoromethyl-benzylamino)prop-1-ylamino)-1H-quinolin-4 -one, used as G-protein coupled receptor inhibitors, for prophylaxis of cardiovascular disorders, schizophrenia or diabetes |
| 02/26/2004 | US20040039016 HIV protease inhibitors |
| 02/26/2004 | US20040039015 Estrogen Receptor-beta ligands |
| 02/26/2004 | US20040039014 Methods and compounds for treating depression and other disorders |
| 02/26/2004 | US20040039011 Administering anticholinergic or bronchodilator agents such as tiotropium bromide for prophylaxis of respiratory system disorders |
| 02/26/2004 | US20040039010 Methods for treatment of acute lymphocytic leukemia |
| 02/26/2004 | US20040039008 Peroxy compounds such as adamantane-2-spiro-3'-8'-((1'S)-10'-camphorsulfonyl)-1',2',4'-trioxa-8' -azaspiro(4.5)decane, used for prophylaxis of malaria or schistosomiasis infections |
| 02/26/2004 | US20040039007 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists |
| 02/26/2004 | US20040039006 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 02/26/2004 | US20040039005 HIV replication inhibiting pyrimidines |
| 02/26/2004 | US20040039004 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders |
| 02/26/2004 | US20040039003 Treatment of hepatic cirrhosis |
| 02/26/2004 | US20040039002 6,7-Dimethoxyquinazolines and therapeutic use thereof |
| 02/26/2004 | US20040039001 2-guanidino-4-aryl-quinazoline |
| 02/26/2004 | US20040038998 Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity |
| 02/26/2004 | US20040038995 Inhibitors of both KDR an FGFR kinases and are selective against LCK; for treatment of solid tumors, in particular breast, colon, lung and prostate tumors. |
| 02/26/2004 | US20040038993 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents |
| 02/26/2004 | US20040038992 2-thio-(or oxy)-5-amino-1,3,4-thiadiazoles or oxadiazoles |
| 02/26/2004 | US20040038991 Imidazolyl-cyclic acetals |
| 02/26/2004 | US20040038989 (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, useful as intermediates for the preparation of levodropropizine |
| 02/26/2004 | US20040038988 Novel crystalline forms of gatifloxacin |
| 02/26/2004 | US20040038985 Treating depression, anxiety, obesity, or urinary incontinence |
| 02/26/2004 | US20040038984 Composition for male & female sexual arousal |
| 02/26/2004 | US20040038983 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof |
| 02/26/2004 | US20040038982 Substituted piperidine or piperazine compounds which are modulators, agonists or antagonists of the CCR5 receptor. |
| 02/26/2004 | US20040038979 Novel 6-heteroarylphenanthridines |
| 02/26/2004 | US20040038978 Chemical compounds |
| 02/26/2004 | US20040038977 Treating arthritis, pain and cancer |
| 02/26/2004 | US20040038976 S,N-diarylsulfonamide derivatives; treating inflammatory diseases such as Celiac's disease, Crohn's disease or colitis. |
| 02/26/2004 | US20040038975 Effective against a broad range of pathogenic microorganisms with advantages in low susceptibility to microbial resistance, reduced toxicity, and improved pharmacology. |
| 02/26/2004 | US20040038974 Antiarthritic agents |
| 02/26/2004 | US20040038969 Substituted aminopyrimidines and aminopyridazines; analgesics particularly for migraines, neuropathic pain and associated hyperalgesia and allodynia; antiinflammatory agents; treating asthma, gastrointestinal disorders, etc. |
| 02/26/2004 | US20040038968 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione potassium salt |
| 02/26/2004 | US20040038966 Cyclic amine derivatives and use thereof |
| 02/26/2004 | US20040038964 Imidazole derivatives as raf kinase inhibitors |
| 02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 02/26/2004 | US20040038962 Treatment of nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence or bleeding disorders such a hemophilia |
| 02/26/2004 | US20040038958 Topical treatment of skin diseases |
| 02/26/2004 | US20040038957 Anti-malarial activity |
| 02/26/2004 | US20040038955 Administering delta 5-androstene-3 beta-ol-7,17 dione and metabolizable precursors thereof, such as the 3-beta acetate |
| 02/26/2004 | US20040038954 Method of treating inflammatory conditions with progesterone or progesterone analogs |
| 02/26/2004 | US20040038953 Medical combination comprising salmeterol and budesonide |
| 02/26/2004 | US20040038952 Combination of a bile acid and a bioflavonoid; also for treating eye disorders and premenstrual symptoms. |
| 02/26/2004 | US20040038951 Organic compounds |
| 02/26/2004 | US20040038950 Pharmaceutical composition for treating IL-1 related diseases or disorders |
| 02/26/2004 | US20040038949 Inhibitors of the enzyme CYP24; useful for treating cell-proliferative disorders and for promoting cell differentiation. |
| 02/26/2004 | US20040038948 Promoting healing through enhanced regeneration of hard or soft tissue contact with an anti-inflammatory agent; useful in treating periodontal diseases and in orthopedic applications. |
| 02/26/2004 | US20040038947 Method of treating ischemia/reperfusion injury with nitroxyl donors |
| 02/26/2004 | US20040038946 Biologically inert carrier (e.g., fullerene); a bone vector (e.g., a bisphosphonate) chemically bonded to the carrier; and a therapeutic agent chemically bonded to the carrier |
| 02/26/2004 | US20040038945 Administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound. |
| 02/26/2004 | US20040038944 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 02/26/2004 | US20040038943 Indole and benzimidazole 15-lipoxygenase inhibitors |
| 02/26/2004 | US20040038942 Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes |
| 02/26/2004 | US20040038941 Compounds for the treatment of inflammatory disorders |
| 02/26/2004 | US20040038940 Processes for preparing substituted aryl boronic acids |
| 02/26/2004 | US20040038939 Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
| 02/26/2004 | US20040038938 Increasing the survival or growth of motoneurons; treating diseases such as amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy and primary lateral sclerosis. |
| 02/26/2004 | US20040038936 Pharmaceutical composition containing viscoelastic substance and medication |
| 02/26/2004 | US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 02/26/2004 | US20040038934 Preparation from bis2-(N'-ethylcarbodimido)ethyldisulfide, hyaluronic acid and a reducing agent; useful in ophthalmic surgery and in tissue engineering. |
| 02/26/2004 | US20040038933 Pharmaceutical compositions, dose and method for treating malaria |
| 02/26/2004 | US20040038932 Antithrombotic compositions |
| 02/26/2004 | US20040038931 High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity |
| 02/26/2004 | US20040038930 Freeze drying the buffered complex, e.g., ferric hydroxide sucrose, sodium ferric gluconate or ferric saccharate, for subsequent reconstitution for parenteral injection; treating iron deficiency anemia |